SK biopharmaceuticals
SK biopharmaceuticals' Korean headquarters and U.S. and Chinese subsidiaries are spearheading the development and commercialization of new drugs, while also seeking and strengthening partnerships for global expansion.
[JPM 2025] SK biopharmaceuticals to establish AI-based epilepsy ...
1 day ago · SK biopharmaceuticals announced it plans to establish a joint venture (JV) with Eurofarma, one of the largest pharmaceutical companies in Latin America, durng the J.P. Morgan Healthcare Conference 2025 in San Francisco, Calif., U.S., on Monday, local time.The strategic move aims to commercialize SK
SK Biopharmaceuticals to establish joint venture in U.S. for biz
SK Biopharm-joint venture SEOUL, Jan. 15 (Yonhap) -- SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major South American ...
SK Biopharma, Eurofarma to Jointly Launch AI-Based Epilepsy …
9 hours ago · SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others.
SK Biopharmaceuticals, Eurofarma to launch telehealth joint …
1 day ago · SK Biopharmaceuticals CEO Lee Dong-hoon announced the initiative on Monday during a news conference in San Francisco, where 43rd J.P. Morgan Healthcare Conference is taking place. “We will be working together to develop an AI model and algorithm to predict seizures using epilepsy data,” Lee said. ...
The Future of Epilepsy Care: Insights from SK’s 100,000 Patient ...
Jan 9, 2025 · In 2020, SK Biopharmaceuticals — a subsidiary of SK Group — developed a new treatment for adults with partial-onset seizures. First launched in the U.S., as XCOPRI® (cenobamate tablets), the FDA-approved treatment has also received approval by the European Commission (EC) and subsequently by Swiss regulator Swissmedic, and the UK’s ...
SK Biopharmaceuticals Announces 100,000 Patients Globally …
Mar 11, 2024 · GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and...
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing …
Jul 17, 2024 · Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets.
SK Biopharmaceuticals Makes Big Bets to be 'Big Biotech' - PR …
Jul 18, 2023 · SK Biopharmaceuticals mobilizes its cutting-edge modality platforms of radiopharmaceutical therapy (RPT), targeted protein degradation (TPD), and cell and gene therapy (CGT) aligning with its...
SK Biopharmaceuticals Assembles 'Board of Prominent Experts' …
SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board (SAB), comprising of five prominent...
- Some results have been removed